Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31022762 | 0.85 | HPGD (0.53) | HPGDKMT2AFGFR1THRBGAK | |
| SCHEMBL29026031 | 0.85 | HPGD (0.53) | HPGDKMT2AFGFR1THRBGAK | |
| SCHEMBL4472032 | 0.81 | FGFR1 (0.75) | HPGDFGFR1THRBTP53MAPK1 | |
| SCHEMBL31633080 | 0.80 | HPGD (0.53) | HPGDKMT2API4KAPI4K2BPI4K2A | |
| SCHEMBL2969109 | 0.79 | HPGD (0.50) | HPGDFGFR1THRB | |
| SCHEMBL13202017 | 0.79 | KMT2A (0.52) | HPGDKMT2AFGFR1PI4KAPI4K2B | |
| SCHEMBL13202015 | 0.77 | TP53 (0.50) | TP53MAPK1SMN1; SMN2MAPT | |
| SCHEMBL31632800 | 0.77 | SCN2B (0.49) | KMT2AMAPK14 | |
| SCHEMBL24463745 | 0.74 | HPGD (0.70) | HPGDKMT2ATP53SMN1; SMN2GAK | |
| SCHEMBL23675268 | 0.74 | HPGD (0.47) | HPGDFGFR1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-7442709-B2 | N3-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442709-B2 | N3-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | disclosed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | KIT, ABL1, CHUK | HPGD 666/4885KMT2A 386/4885FGFR1 1014/4885 |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | KIT, ABL1, CHUK | HPGD 1281/4885KMT2A 333/4885FGFR1 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.